Effects of dexamethasone on pulmonary and renal functions in patients undergoing CABG with cardiopulmonary bypass

Area of Science:

• Anesthesiology
• Cardiothoracic Surgery
• Nephrology
• Pulmonology

Background:

• Coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) can lead to renal and pulmonary complications.
• Dexamethasone, a corticosteroid, is sometimes used perioperatively, but its effects on outcomes in CABG patients are not fully elucidated.

Purpose of the Study:

• To evaluate the efficacy of dexamethasone in improving renal and pulmonary outcomes in patients undergoing CABG with CPB.
• To assess the impact of dexamethasone on extubation time and hyperglycemia.

Main Methods:

• A randomized controlled trial involving 100 patients undergoing CABG with CPB.
• Patients received either placebo or dexamethasone (1 mg/kg at induction and 0.5 mg/kg 8 hours later).
• Renal function (creatinine clearance, urinary microalbumin, NAG) and pulmonary parameters (A-a O2 gradient, respiratory index, PaO2/FiO2) were monitored.

Main Results:

• Dexamethasone showed no significant renal protective effect, with comparable creatinine clearance, urinary microalbumin, and NAG levels between groups.
• Significant improvements in A-a O2 gradient, respiratory index, and PaO2/FiO2 ratio were observed at 12 and 24 hours postoperatively in the dexamethasone group.
• No significant difference in extubation time was noted. Hyperglycemia was more frequent in the dexamethasone group.

Conclusions:

• Dexamethasone does not provide renal protection in CABG patients undergoing CPB.
• The drug significantly improves specific pulmonary parameters postoperatively but does not impact extubation time.
• Increased risk of hyperglycemia is associated with dexamethasone use in this patient population.